We are monitoring the impact of COVID-19 on APAC ADHD Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 267
Share on
Share on

APAC ADHD Therapeutics Market Research Report – Segmented Treatment By Medication, Psychotherapy, Education or Training & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) – Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 267
Pages: 140

APAC ADHD Therapeutics Market Size (2021 to 2026)

As per our report, the size of the attention deficit hyperactivity disorder (ADHD) therapeutics market in the Asia Pacific has been estimated at USD 2.23 billion in 2021 and is predicted to reach USD 3.99 billion by 2026, growing at a CAGR of 12.30% from 2021 to 2026.

The growing prevalence of attention deficit hyperactivity disorder among children, which is due to preterm, low birth weight of infants and increase in the constant environmental changes, unhealthy lifestyle, genetic factors, is majorly driving the growth of the ADHD therapeutics market in the APAC region. However, the occurrence of ADHD is primarily seen in the 4-8 or less than 12 years of age group.

The growing population is significantly contributing to the APAC ADHD therapeutics market growth. On the other hand, the increase in mental disorders among children, the rising investments from government and non-government organizations for developing various treatments and therapies for treating the conditions related to mental illness are expected to propel the market growth. 

In addition, the increase in the initiatives for developing medical and health care awareness and infrastructure in the region is propelling the growth of the ADHD therapeutics market. Furthermore, the rising awareness about mental illness and disorders among the people also for providing better treatment and therapies for the conditions is expected to influence market growth positively. Also, the increase in screening tests and diagnostic procedures is expected to drive market growth. Furthermore, the growing competition between the players for developing new and effective products and medications by applying various strategies such as mergers and acquisitions is uplifting the growth in the ADHD therapeutics market in the APAC region.

However, the increase in the high costs of the treatment and procedures with the lack of proper reimbursement policies affects the market's growth. In addition, the issues related to the medication of the ADHD therapeutics, such as side effects, infection like allergies, anorexia, headaches, and other effects, are limiting the market's growth. On the other hand, the strict government rules and regulations for introducing a new product in the market with stringent approval procedures for approving new entry products are the other factors limiting the growth of the ADHD therapeutics market in the APAC region.

This research report on the APAC ADHD Therapeutics Market has been segmented and sub-segmented into the following categories:

By Medication:

  • Stimulants
  • Non-Stimulants

By Psychotherapy:

  • Behaviour Therapy
  • Cognitive Behavioural Therapy
  • Interpersonal Psychotherapy
  • Family Therapy

By Education Or Training:

  • Parent Management Training
  • Social Skills Training
  • School-Based Interventions

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

The Asia Pacific market is projected to account for the highest share of the global ADHD therapeutics market during the forecast period. The market is expected to grow owing to the number of patients with ADHD, the increase in investments from government and non-government firms. According to a study on the rise in the prevalence of ADHD in primary school children is accounted as 11.32 percent in India; further, the study has shown that the probability of ADHD in males is higher than females that is 66.7 percent in males 16.33 percent in females. Also, the prevalence of ADHD in Australia among children is propelling the growth of the market. The major growth contributors in the region are China, India, and Japan.

However, China dominated the APAC ADHD therapeutics market in 2020. The factors such as an increase in the early adoption of new and advanced technology with the increasing initiatives for raising awareness among the people for growing medical and healthcare expenditure is driving the market growth of the ADHD therapeutics in the country.

KEY MARKET PLAYERS:

A few of the promising companies in the APAC attention deficit hyperactivity disorder (ADHD) therapeutics market profiled in this report are Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.) and Curemark, LLC. (U.S.).

  1. Introduction

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                          

                1.4 General Study Assumptions                                

  1. Research Methodology

                2.1 Introduction                                               

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                           

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                      

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

  1. Overview

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                                              

  1. Market Segmentation

                5.1 Introduction                                               

                5.2 Treatment By Medication                                    

                                5.2.1 Introduction                           

                                5.2.2 Stimulants                               

                                                5.2.2.1 Introduction       

                                                5.2.2.2 Amphetamines 

                                                5.2.2.3 Methylphenidate             

                                                5.2.2.4 Dextroamphetamine      

                                                5.2.2.5 Dexmethylphenidate     

                                5.2.3 Non-Stimulants                     

                                                5.2.3.1 Introduction       

                                                5.2.3.2 Atomoxetine      

                                                5.2.3.3 Bupropion           

                                                5.2.3.4 Guanfacine         

                5.3 Treatment By Psychotherapy                                             

                                5.3.1 Introduction                           

                                5.3.2 Behavior Therapy                 

                                5.3.3 Cognitive Behavioral Therapy                         

                                5.3.4 Interpersonal Psychotherapy                         

                                5.3.5 Family Therapy                      

                5.4 Treatment By Education or Training                                 

                                5.3.1 Introduction                           

                                5.3.2 Parent Management Training                         

                                5.3.3 Social Skills Training                             

                                5.3.4 School-Based Interventions                            

  1. Geographical Analysis

                6.3 Asia-Pacific                                 

                                6.3.1 Introduction                           

                                6.3.2 China                         

                                6.3.3 India                          

                                6.3.4 Japan                         

                                6.3.5 Australia                   

                                6.3.6 Soth Korea                              

  1. Strategic Analysis

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                       

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services                              

                                7.2.5 Competitive Rivalry within the Industry                     

  1. Market Leaders' Analysis

                8.1 Shire plc (Ireland)                                    

                                8.1.1 Overview                 

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                             

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Neos Therapeutics, Inc. (U.S.)                                            

                8.3 Eli Lilly and Company (U.S.)                                  

                8.4 Pfizer Inc. (U.S.)                                       

                8.5 Alcobra Ltd. (Israel)                                 

                8.6 Supernus Pharmaceuticals, Inc. (U.S.)                                            

                8.7 Noven Pharmaceuticals, Inc. (U.S.)                                  

                8.8 Novartis AG (Switzerland)                                    

                8.9 Johnson & Johnson (U.S.)                                    

                8.10 Curemark, LLC., (U.S.)                                         

  1. Competitive Landscape

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                       

                9.3 Agreements, collaborations and Joint Ventures                                         

                9.4 New Product Launches                                         

  1. Expert Opinions

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 

     Appendix                                                          

a) List of Tables

b) List of Figures

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Attention-Deficit Hyperactivity Disorder Therapeutics Market By Region, From 2021 to 2026 (USD Billion)
  2. Asia-Pacific Attention-Deficit Hyperactivity Disorder Therapeutics Market By Medication, From 2021 to 2026 (USD Billion)
  3. Asia-Pacific Stimulants Market By Region, From 2021 to 2026 (USD Billion)
  4. Asia-Pacific Non-Stimulants Market By Region, From 2021 to 2026 (USD Billion)
  5. Asia-Pacific Attention-Deficit Hyperactivity Disorder Therapeutics Market By Psychotherapy, From 2021 to 2026 (USD Billion)
  6. Asia-Pacific Behavior Therapy ADHD Therapeutics Market By Region, From 2021 to 2026 (USD Billion)
  7. Asia-Pacific Cognitive Behavioral Therapy ADHD Therapeutics Market By Region, From 2021 to 2026 (USD Billion)
  8. Asia-Pacific Interpersonal Psychotherapy ADHD Therapeutics Market By Region, From 2021 to 2026 (USD Billion)
  9. Asia-Pacific Family Therapy ADHD Therapeutics Market By Region, From 2021 to 2026 (USD Billion)
  10. Asia-Pacific Attention-Deficit Hyperactivity Disorder Therapeutics Market By Education or Training, From 2021 to 2026 (USD Billion)
  11. Asia-Pacific Parent Management Training ADHD Therapeutics Market By Region, From 2021 to 2026 (USD Billion)
  12. Asia-Pacific Social Skills Training ADHD Therapeutics Market By Region, From 2021 to 2026 (USD Billion)
  13. Asia-Pacific School-based Interventions ADHD Therapeutics Market By Region, From 2021 to 2026 (USD Billion)
  14. China Attention-Deficit Hyperactivity Disorder Therapeutics Market By Medication, From 2021 to 2026 (USD Billion)
  15. China Attention-Deficit Hyperactivity Disorder Therapeutics Market By Psychotherapy, From 2021 to 2026 (USD Billion)
  16. China Attention-Deficit Hyperactivity Disorder Therapeutics Market By Education or Training, From 2021 to 2026 (USD Billion)
  17. India Attention-Deficit Hyperactivity Disorder Therapeutics Market By Medication, From 2021 to 2026 (USD Billion)
  18. India Attention-Deficit Hyperactivity Disorder Therapeutics Market By Psychotherapy, From 2021 to 2026 (USD Billion)
  19. India Attention-Deficit Hyperactivity Disorder Therapeutics Market By Education or Training, From 2021 to 2026 (USD Billion)
  20. Japan Attention-Deficit Hyperactivity Disorder Therapeutics Market By Medication, From 2021 to 2026 (USD Billion)
  21. Japan Attention-Deficit Hyperactivity Disorder Therapeutics Market By Psychotherapy, From 2021 to 2026 (USD Billion)
  22. Japan Attention-Deficit Hyperactivity Disorder Therapeutics Market By Education or Training, From 2021 to 2026 (USD Billion)
  23. South Korea Attention-Deficit Hyperactivity Disorder Therapeutics Market By Medication, From 2021 to 2026 (USD Billion)
  24. South Korea Attention-Deficit Hyperactivity Disorder Therapeutics Market By Psychotherapy, From 2021 to 2026 (USD Billion)
  25. South Korea Attention-Deficit Hyperactivity Disorder Therapeutics Market By Education or Training, From 2021 to 2026 (USD Billion)
  26. Australia Attention-Deficit Hyperactivity Disorder Therapeutics Market By Medication, From 2021 to 2026 (USD Billion)
  27. Australia Attention-Deficit Hyperactivity Disorder Therapeutics Market By Psychotherapy, From 2021 to 2026 (USD Billion)
  28. Australia Attention-Deficit Hyperactivity Disorder Therapeutics Market By Education or Training, From 2021 to 2026 (USD Billion)
  29. Asia-Pacific Stimulants ADHD Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  30. Asia-Pacific Amphetamines Market By Region, From 2021 to 2026 (USD Billion)
  31. Asia-Pacific Methylphenidate Market By Region, From 2021 to 2026 (USD Billion)
  32. Asia-Pacific Dextroamphetamine Market By Region, From 2021 to 2026 (USD Billion)
  33. Asia-Pacific Dexmethylphenidate Market By Region, From 2021 to 2026 (USD Billion)
  34. China Stimulants ADHD Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  35. India Stimulants ADHD Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  36. Japan Stimulants ADHD Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  37. South Korea Stimulants ADHD Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  38. Australia Stimulants ADHD Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  39. Asia-Pacific Non-Stimulants ADHD Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  40. Asia-Pacific Atomoxetine Market By Region, From 2021 to 2026 (USD Billion)
  41. Asia-Pacific Bupropion Market By Region, From 2021 to 2026 (USD Billion)
  42. Asia-Pacific Guanfacine Market By Region, From 2021 to 2026 (USD Billion)
  43. China Non-Stimulants ADHD Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  44. India Non-Stimulants ADHD Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  45. Japan Non-Stimulants ADHD Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  46. South Korea Non-Stimulants ADHD Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  47. Australia Non-Stimulants ADHD Therapeutics Market By Type, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample